Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elite PharmaceuticalsELTP -3.24%60 Earnings Yield (Joel Greenblatt) % is 15.72% as of Mar. 2026, which is 2520% above its 10-year median of 0.60. GuruFocus rates ELTP with a GF Score™ of 60/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,010 Drug Manufacturers companies, Elite Pharmaceuticals ranks better than 90.4% on this metric.
Elite Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was $363.9 Mil.
Elite Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $57.2 Mil. Elite Pharmaceuticals's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 15.72%.
The historical rank and industry rank for Elite Pharmaceuticals's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
ELTP'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -25.07 Med: 0.6 Max: 22.39
Current: 15.75
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Elite Pharmaceuticals was 22.39%. The lowest was -25.07%. And the median was 0.60%.
ELTP's Earnings Yield (Joel Greenblatt) % is ranked better than 90.4% of 1010
companies
in the Drug Manufacturers industry
Industry Median: 3.325
vs ELTP: 15.75
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Elite Pharmaceuticals's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Elite Pharmaceuticals Earnings Yield (Joel Greenblatt) % Related Terms
Elite Pharmaceuticals Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Elite Pharmaceuticals's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Elite Pharmaceuticalss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
Elite Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $57.2 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 15.72% mean?
Elite Pharmaceuticals (ELTP) has a Earnings Yield (Joel Greenblatt) % of 15.72% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Elite Pharmaceuticals and its competitors. This is 2520% above median its historical median of 0.60. According to the industry distribution chart, Elite Pharmaceuticals ranks #97 out of 1010 companies in the Drug Manufacturers industry, placing it in the top 9.6%.
Is Elite Pharmaceuticals' Earnings Yield (Joel Greenblatt) % too high?
Elite Pharmaceuticals' current Earnings Yield (Joel Greenblatt) % of 15.72% is 2520% above median its 10-year median of 0.60. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.33. Elite Pharmaceuticals' value of 15.72% is 372.8% above this industry median. Based on the distribution chart, Elite Pharmaceuticals ranks #97 out of 1010 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Elite Pharmaceuticals has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Earnings Yield (Joel Greenblatt) % compare to EOLS and EBS?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #97 out of 1010 companies for Earnings Yield (Joel Greenblatt) %. This places Elite Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.33. Elite Pharmaceuticals' value of 15.72% is 372.8% above this benchmark. While the company's 10-year median is 0.60 vs. the industry median of 3.33, Elite Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.33, based on 1,010 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elite Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % of 15.72% is 372.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Elite Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % is 15.72%, which is 2520% above median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.36 — trading 36.9% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 15.72%, which is 2520% above median its 10-year median of 0.60 and 372.8% above the Drug Manufacturers industry median of 3.33. Elite Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Earnings Yield (Joel Greenblatt) % is 15.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.36 is trading 36.9% below its estimated GF Value™ of $0.57.
GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ELTP:
Earnings Yield (Joel Greenblatt) %: 15.72% (2520% above median its 10-year median of 0.60)
GF Value™: $0.57 vs. price of $0.36 (36.9% below fair value)
Industry Position: 372.8% above the Drug Manufacturers median (#97 of 1010)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
60GF Score
Get the complete analysis for ELTP
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 
